PTC Therapeutics discovers and develops small molecule drugs by applying its integrated RNA biology and chemistry platforms. PTC’s compounds modulate gene expression by selectively binding to either RNA targets or to proteins that interact with RNA. This approach has advanced PTC’s programs rapidly from targets to preclinical and clinical drug candidates.
PTC Therapeutics completed an Initial Public Offering in June 2013 (NASDAQ: PTCT).